News | June 12, 2021
IPCA Laboratories increases stake in Trophic Wellness to 52.35%
With the acquisition of these further shares, TWPL has now become company's subsidiary.
With the acquisition of these further shares, TWPL has now become company's subsidiary.
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
The company plans to enter the EU markets in FY22
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
The price increases are due to the rising costs of raw materials.
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
